Pfizer-BioNTech/Comirnaty COVID-19 mRNA Vaccine (nucleoside modified)

• On 14 January 2021, the Food and Drug Administration (FDA) issued authorization (amended on 14 June 2022) granting Pfizer, Inc. the emergency use approval of Pfizer-BioNTech COVID-19 Vaccine.
• Further, on 14 January 2021, the Food and Drug Administration (FDA) issued authorization (amended on 14 June 2022) granting Pfizer, Inc. the emergency use approval of Comirnaty COVID-19 mRNA Vaccine (nucleoside modified). On 24 December 2021, the FDA issued emergency use authorization (amended on 14 June 2022) to Pfizer, Inc. for Comirnaty Covid-19 mRNA Vaccine (nucleoside modified) – Dispersion for Injection (no dilution). 
• On 22 December 2021, the FDA issued authorization (amended on 26 April 2022) granting Pfizer, Inc. the emergency use approval of Comirnaty COVID-19 mRNA Vaccine (nucleoside modified)-for children. 

Product Information                                                          Product Information (Vaccine for Children)

  For Vaccine Recipients                                                       For Vaccine Recipients

 For Healthcare Providers                                                     For Healthcare Providers

• For more information on reporting side effects, click here.